Abstract: The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof. The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).

Abstract: The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof. The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).

Abstract: The present invention relates to an improved process for the preparation of substantially pure Amifampridine phosphate The present invention further relates to a substantially pure Amifampridine Phosphate, useful for the preparation of pharmaceutical composition thereof.

Abstract: The present invention provides process for preparation of Fingolimod hydrochloride (I). Fingolimod hydrochloride (I) as Form-? obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.

Abstract: The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2?° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2?°, DSC isotherm comprising the endothermic peaks ranging between 213 to 217° C. (Peak ?1) and 225 to 235° C. (Peak ?2) and IR absorption characteristic peaks at approximately 3278 cm?1, 1948 cm?1, 1871 cm?1, 1632 cm?1, 1164 cm?1, 1024 cm?1, 940 cm?1 and 742 cm?1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.

Abstract: The present invention relates to a process for preparation of dimethyl-(E)-butenedioate(I). The process for preparation of dimethyl-(E)-butenedioate (I), comprises reaction of Fumaric acid with methanol in the presence of C2-C4alkanoyl halideas coupling catalyst.

Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.

Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.

Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.

Abstract: The present invention provides process for preparation of Fingolimod hydrochloride (I). Fingolimod hydrochloride (I) as Form-? obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.

Abstract: The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2?° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2?°, DSC isotherm comprising the endothermic peaks ranging between 213 to 217° C. (Peak -1) and 225 to 235° C. (Peak -2) and IR absorption characteristic peaks at approximately 3278 cm?1, 1948 cm?1, 1871 cm?1, 1632 cm?1, 1164 cm?1, 1024 cm?1, 940 cm?1 and 742 cm?1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.

Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.